Abstract
Corpus callosum dysgenesis is one of the most common congenital neurological malformations. Despite being a clear and identifiable structural alteration of the brain’s white matter connectivity, the impact of corpus callosum dysgenesis on cognition and behaviour has remained unclear. Here we build upon past clinical observations in the literature to define the clinical phenotype of corpus callosum dysgenesis better using unadjusted and adjusted group differences compared with a neurotypical sample on a range of social and cognitive measures that have been previously reported to be impacted by a corpus callosum dysgenesis diagnosis. Those with a diagnosis of corpus callosum dysgenesis (n = 22) demonstrated significantly higher persuadability, credulity, and insensitivity to social trickery than neurotypical (n = 86) participants, after controlling for age, sex, education, autistic-like traits, social intelligence, and general cognition. To explore this further, machine learning, utilising a set neurotypical sample for training the normative covariance structure of our psychometric variables, was used to test whether these dimensions possessed the capability to discriminate between a test-set of neurotypical and corpus callosum dysgenesis participants. We found that participants with a diagnosis of corpus callosum dysgenesis were best classed within dimension space along the same axis as persuadability, credulity, and insensitivity to social trickery after controlling for age and sex, with Leave-One-Out-Cross-Validation across 250 training-set permutations providing a mean accuracy of 71.7%. These results have wide- reaching implications for a) the characterisation of corpus callosum dysgenesis, and b) the role of the corpus callosum in social inference.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by a Discovery Project 210101712 from the Australian Research Council (LJR), Washington University in St Louis School of Medicine laboratory start-up funds (LJR), the Max Planck Society (PD) and the Alexander von Humboldt Foundation (PD). GAR was supported by an Australian National Health and Medical Research Council Fellowship (APP1135769) and the Brazil Family Program for Neurology. LJR was supported by a Principal Research Fellowship from the National Health and Medical Research Council (GNT1120615).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All procedures relating to this study were approved by the University of Queensland human research ethics committee (approval ref: 2014/HE000535), and the design of the study itself was created with input from sitting members of the Executive Committee of AusDoCC.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Author order was changed in the upload
Data Availability
All anonymised data and analysis code are available for free from https://github.com/Brain-Development-and-Disorders-Lab.
Abbreviations
- AQ
- Autism Quotient
- ASD
- Autism Spectrum Disorder
- CCD
- Corpus Callosum Dysgenesis
- ETQ
- Epistemic Trust Questionnaire
- GS
- Gullibility Scale
- ICAR
- International Cognitive Ability Resource (Progressive Matrices)
- ICC
- Intraclass Correlation Coefficient
- LOOCV
- Leave-One-Out-Cross-Validation
- McA-SL
- MacArthur Social Ladder
- NT
- Neurotypical
- PC
- Principal Component
- R-GPTS
- Revised Green Paranoid Thoughts Scale
- SIS
- Social Intelligence Scale.
